Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

Bloomberg Markets

Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales

Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales
ShareXFacebook

Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies flood the market.

B

Source

Bloomberg Markets

Read full article at Bloomberg Markets

Opens original article in a new tab

Advertisement

Related Economy Stories

Advertisement